MRFF - Clinical Trials Activity Initiative - 2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19 Grant
The objective of this Grant Opportunity is to utilise clinical trials to investigate effective mechanisms for the prevention or treatment of COVID-19 or its symptoms. Applications must propose a clinical trial that addresses a gap in current research and/or knowledge in with a specific focus on COVID-19.The intended outcome of this research is to deliver high quality evidence of strategies for the prevention or treatment of COVID-19 or its symptoms that can be translated into policy or practice.
To be competitive for funding, applicants must propose to conduct a single clinical trial that delivers against the above objectives. Clinical trials should not have commenced recruitment; however new treatment arms of established Australian and international trials will also be considered.
For this grant opportunity there is up to $25M of funding available over three years from 2020-21. There is no maximum amount but grants cannot exceed the amount of available funds. A CI can only be named on a maximum of one application to this opportunity.
For more details about the opportunity, please see Grant Connect.
Research Development Support
The Research Development Team is available to provide advice to applicants on how to address the assessment criteria effectively and for strategic review of complete drafts. We encourage researchers to seek this support earlier rather than later, as capacity is limited and time should be allowed for a compliance check, noting the dates specified by the MHS team.
Please contact Gabrielle Callander or Karen McConalogue as soon as possible to discuss your application.
-------- // --------
Key Dates
- 20 Aug 2020: Call opened
- 9 Sep 2020: (17:00 ACT local time) Minimum Data deadline (in Sapphire; mandatory)
- 9 Sep 2020: MRO Compliance Deadline (eligibility & compliance review, via Pure)
- 23 Sep 2020: (17:00 ACT local time) Applications close (in Sapphire)
No comments:
Post a Comment